 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of CYP450 Interactions with Warfarin Enzyme [0m
[31mInhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, [0m
[31mvoriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine[0m
[31mWARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton [0m
[31mmontelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, [0m
[31mcimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenav WARFARIN: drug_interactions: ir, [0m
[31mimatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, [0m
[31mtelithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, [0m
[31mrifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN: drug_interactions: Because bleeding risk is [0m
[31mincreased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: drug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk [0m
[31mof Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, [0m
[31mticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, [0m
[31msulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, [0m
[31mvilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown [0m
[31mconsistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m [0m
[31mProducts and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, well-controlled studies evaluating the potential for metabolic and/or [0m
[31mpharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may [0m
[31mvary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals may cause bleeding events when taken alone [0m[1;31m([0m[31me.g. WARFARIN: [0m
[31mdrug_interactions: garlic and Ginkgo biloba[0m[1;31m)[0m[31m and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of [0m
[31mwarfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium [0m[1;31m([0m[31me.g., co-enzyme Q [0m[1;31m10[0m[31m , St. Johnâ€™s wort, ginseng[0m[1;31m)[0m[31m. Some botanicals and foods can interact with warfarin sodium [0m
[31mthrough CYP450 interactions [0m[1;31m([0m[31me.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. Johnâ€™s wort[0m[1;31m)[0m[31m. The amount of vitamin K in food may affect therapy with warfarin sodium. Advise patients taking [0m
[31mwarfarin sodium to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking warfarin sodium should avoid drastic changes in dietary habits, such as eating large [0m
[31mamounts of green leafy vegetables.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. [0m
[31mDiscontinue warfarin sodium and consider alternative anticoagulants if necessary. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Calciphylaxis: Fatal and serious cases have occurred. Discontinue warfarin sodium and consider alternative [0m
[31manticoagulation therapy. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Systemic atheroemboli and cholesterol microemboli: Some cases have [0m
[31mprogressed to necrosis or death. Discontinue warfarin sodium if such emboli occur. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m: Initial therapy with warfarin sodium in HIT has resulted in cases of [0m
[31mamputation and death. WARFARIN: warnings_and_cautions: Warfarin sodium may be considered after platelet count has normalized. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m Pregnant women with mechanical heart valves: Warfarin sodium may [0m
[31mcause fetal harm; however, the benefits may outweigh the risks. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Hemorrhage Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk [0m
[31mfactors for bleeding include high intensity of anticoagulation [0m[1;31m([0m[31mINR > [0m[1;31m4[0m[1;31m)[0m[31m, age greater than or equal to [0m[1;31m65[0m[31m, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, [0m
[31mcerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [0m[31m , certain concomitant drugs [0m[31m , and long duration of warfarin therapy. Perform regular monitoring of INR [0m
[31min all treated patients. WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration [0m
[31mof therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR [0m
[31mlevels achieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct [0m
[31mpatients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other[0m
[31mtissues, which is an uncommon but serious risk [0m[1;31m([0m[1;31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin[0m
[31msodium therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to [0m
[31mdetermine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin [0m
[31msodium therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium [0m
[31muremic arteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat [0m
[31mcalciphylaxis as appropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: <table [0m[31mwidth[0m[31m=[0m[31m"1000px"[0m[31m><col/><col/><tbody><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule [0m
[31mRrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Warfarin <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31mwar&apos; far in[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> Sodium <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31msoe&apos; dee um[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> [0m
[31mTablets<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule Rrule"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule [0m
[31mRrule"[0m[31m><content style WARFARIN: spl_medguide_table: [0m[31mCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium tablets?<[0m[31m/[0m[31mcontent[0m[31m><paragraph>Warfarin sodium tablets can [0m
[31mcause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. [0m
[31mWARFARIN: spl_medguide_table: <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>You may have a higher risk of bleeding if you take warfarin sodium tablets and: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>are [0m[1;31m65[0m[31m years of age or older <[0m[31m/[0m[31mitem[0m[31m><item>have a history of stomach or intestinal bleeding <[0m[31m/[0m[31mitem[0m[31m><item>have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have a history of [0m
[31mstroke, or &#x201C;mini-stroke&#x201D; [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have serious heart disease <[0m[31m/[0m[31mitem[0m[31m><item>have a low blood count or cancer <[0m[31m/[0m[31mitem[0m[31m><item>have had trauma, such as an[0m
[31maccident or surgery <[0m[31m/[0m[31mitem[0m[31m><item>have kidney problems <[0m[31m/[0m[31mitem[0m[31m><item>take other medicines that increase your risk of bleeding, including: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Square"[0m[31m><item>a medicine [0m
[31mthat contains heparin <[0m[31m/[0m[31mitem[0m[31m WARFARIN: spl_medguide_table: ><item>other medicines to prevent or treat blood clots <[0m[31m/[0m[31mitem[0m[31m><item>non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>take warfarin sodium for a long time. Warfarin sodium is the active ingredient in warfarin sodium tablets. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any[0m
[31mof your medicines or start any new medicines before you talk to your healthcare provider. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not take other medicines that contain warfarin sodium [0m
[31mwhile taking warfarin sodium tablets. WARFARIN: spl_medguide_table: content><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Get your regular blood test to check[0m
[31mfor your response to warfarin sodium tablets. <[0m[31m/[0m[31mcontent[0m[1;31m>[0m[31mThis blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR [0m
[31mnumbers are best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of [0m
[31mthromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [0m[31m . Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a [0m
[31mpattern of congenital malformations in about [0m[1;31m5[0m[31m% of exposed offspring. Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an [0m
[31madequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks [0m
[31mof warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman. WARFARIN: pregnancy: Adverse outcomes in pregnancy occur regardless of the health of the mother[0m
[31mor the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk [0m
[31mof major birth defects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions In humans, warfarin [0m
[31mcrosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in [0m
[31mabout [0m[1;31m5[0m[31m% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses [0m[1;31m([0m[31mchondrodysplasia punctata[0m[1;31m)[0m[31m and growth retardation [0m[1;31m([0m[31mincluding low birth [0m
[31mweight[0m[1;31m)[0m[31m. WARFARIN: pregnancy: Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker [0m
[31mmalformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse [0m
[31mpregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: boxed_warning: WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [0m[31m . Perform regular monitoring of INR in all treated patients [0m[31m . Drugs, dietary changes, and [0m
[31mother factors affect INR levels achieved with warfarin sodium therapy [0m[31m . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m
[31mWARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Perform regular monitoring of INR in all treated [0m
[31mpatients. [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m [0m[1;31m)[0m[31m Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Instruct patients about prevention measures to [0m
[31mminimize risk of bleeding and to report signs and symptoms of bleeding. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m17[0m[31m [0m[1;31m)[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does WARFARIN increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of CYP450 Interactions with Warfarin Enzyme [0m
[31mInhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, [0m
[31mvoriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine[0m
[31mWARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton [0m
[31mmontelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, [0m
[31mcimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenav WARFARIN: drug_interactions: ir, [0m
[31mimatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, [0m
[31mtelithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, [0m
[31mrifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN: drug_interactions: Because bleeding risk is [0m
[31mincreased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: drug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk [0m
[31mof Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, [0m
[31mticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, [0m
[31msulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, [0m
[31mvilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown [0m
[31mconsistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m [0m
[31mProducts and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, well-controlled studies evaluating the potential for metabolic and/or [0m
[31mpharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may [0m
[31mvary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals may cause bleeding events when taken alone [0m[1;31m([0m[31me.g. WARFARIN: [0m
[31mdrug_interactions: garlic and Ginkgo biloba[0m[1;31m)[0m[31m and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of [0m
[31mwarfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium [0m[1;31m([0m[31me.g., co-enzyme Q [0m[1;31m10[0m[31m , St. Johnâ€™s wort, ginseng[0m[1;31m)[0m[31m. Some botanicals and foods can interact with warfarin sodium [0m
[31mthrough CYP450 interactions [0m[1;31m([0m[31me.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. Johnâ€™s wort[0m[1;31m)[0m[31m. The amount of vitamin K in food may affect therapy with warfarin sodium. Advise patients taking [0m
[31mwarfarin sodium to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking warfarin sodium should avoid drastic changes in dietary habits, such as eating large [0m
[31mamounts of green leafy vegetables.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. [0m
[31mDiscontinue warfarin sodium and consider alternative anticoagulants if necessary. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Calciphylaxis: Fatal and serious cases have occurred. Discontinue warfarin sodium and consider alternative [0m
[31manticoagulation therapy. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Systemic atheroemboli and cholesterol microemboli: Some cases have [0m
[31mprogressed to necrosis or death. Discontinue warfarin sodium if such emboli occur. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m: Initial therapy with warfarin sodium in HIT has resulted in cases of [0m
[31mamputation and death. WARFARIN: warnings_and_cautions: Warfarin sodium may be considered after platelet count has normalized. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m Pregnant women with mechanical heart valves: Warfarin sodium may [0m
[31mcause fetal harm; however, the benefits may outweigh the risks. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Hemorrhage Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk [0m
[31mfactors for bleeding include high intensity of anticoagulation [0m[1;31m([0m[31mINR > [0m[1;31m4[0m[1;31m)[0m[31m, age greater than or equal to [0m[1;31m65[0m[31m, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, [0m
[31mcerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [0m[31m , certain concomitant drugs [0m[31m , and long duration of warfarin therapy. Perform regular monitoring of INR [0m
[31min all treated patients. WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration [0m
[31mof therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR [0m
[31mlevels achieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct [0m
[31mpatients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other[0m
[31mtissues, which is an uncommon but serious risk [0m[1;31m([0m[1;31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin[0m
[31msodium therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to [0m
[31mdetermine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin [0m
[31msodium therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium [0m
[31muremic arteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat [0m
[31mcalciphylaxis as appropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: <table [0m[31mwidth[0m[31m=[0m[31m"1000px"[0m[31m><col/><col/><tbody><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule [0m
[31mRrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Warfarin <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31mwar&apos; far in[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> Sodium <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31msoe&apos; dee um[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> [0m
[31mTablets<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule Rrule"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule [0m
[31mRrule"[0m[31m><content style WARFARIN: spl_medguide_table: [0m[31mCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium tablets?<[0m[31m/[0m[31mcontent[0m[31m><paragraph>Warfarin sodium tablets can [0m
[31mcause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. [0m
[31mWARFARIN: spl_medguide_table: <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>You may have a higher risk of bleeding if you take warfarin sodium tablets and: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>are [0m[1;31m65[0m[31m years of age or older <[0m[31m/[0m[31mitem[0m[31m><item>have a history of stomach or intestinal bleeding <[0m[31m/[0m[31mitem[0m[31m><item>have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have a history of [0m
[31mstroke, or &#x201C;mini-stroke&#x201D; [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have serious heart disease <[0m[31m/[0m[31mitem[0m[31m><item>have a low blood count or cancer <[0m[31m/[0m[31mitem[0m[31m><item>have had trauma, such as an[0m
[31maccident or surgery <[0m[31m/[0m[31mitem[0m[31m><item>have kidney problems <[0m[31m/[0m[31mitem[0m[31m><item>take other medicines that increase your risk of bleeding, including: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Square"[0m[31m><item>a medicine [0m
[31mthat contains heparin <[0m[31m/[0m[31mitem[0m[31m WARFARIN: spl_medguide_table: ><item>other medicines to prevent or treat blood clots <[0m[31m/[0m[31mitem[0m[31m><item>non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>take warfarin sodium for a long time. Warfarin sodium is the active ingredient in warfarin sodium tablets. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any[0m
[31mof your medicines or start any new medicines before you talk to your healthcare provider. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not take other medicines that contain warfarin sodium [0m
[31mwhile taking warfarin sodium tablets. WARFARIN: spl_medguide_table: content><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Get your regular blood test to check[0m
[31mfor your response to warfarin sodium tablets. <[0m[31m/[0m[31mcontent[0m[1;31m>[0m[31mThis blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR [0m
[31mnumbers are best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of [0m
[31mthromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [0m[31m . Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a [0m
[31mpattern of congenital malformations in about [0m[1;31m5[0m[31m% of exposed offspring. Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an [0m
[31madequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks [0m
[31mof warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman. WARFARIN: pregnancy: Adverse outcomes in pregnancy occur regardless of the health of the mother[0m
[31mor the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk [0m
[31mof major birth defects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions In humans, warfarin [0m
[31mcrosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in [0m
[31mabout [0m[1;31m5[0m[31m% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses [0m[1;31m([0m[31mchondrodysplasia punctata[0m[1;31m)[0m[31m and growth retardation [0m[1;31m([0m[31mincluding low birth [0m
[31mweight[0m[1;31m)[0m[31m. WARFARIN: pregnancy: Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker [0m
[31mmalformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse [0m
[31mpregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: boxed_warning: WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [0m[31m . Perform regular monitoring of INR in all treated patients [0m[31m . Drugs, dietary changes, and [0m
[31mother factors affect INR levels achieved with warfarin sodium therapy [0m[31m . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m
[31mWARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Perform regular monitoring of INR in all treated [0m
[31mpatients. [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m [0m[1;31m)[0m[31m Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Instruct patients about prevention measures to [0m
[31mminimize risk of bleeding and to report signs and symptoms of bleeding. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m17[0m[31m [0m[1;31m)[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does WARFARIN decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: WARFARIN: boxed_warning: WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [0m[31m . Perform regular monitoring of INR in all treated patients [0m[31m . Drugs, dietary changes, and [0m
[31mother factors affect INR levels achieved with warfarin sodium therapy [0m[31m . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m
[31mWARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Perform regular monitoring of INR in all treated [0m
[31mpatients. [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m [0m[1;31m)[0m[31m Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Instruct patients about prevention measures to [0m
[31mminimize risk of bleeding and to report signs and symptoms of bleeding. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m17[0m[31m [0m[1;31m)[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_set_id         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"1000px"[0m[31m><col/><col/><tbody><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule [0m
[31mRrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Warfarin <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31mwar&apos; far in[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> Sodium <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31msoe&apos; dee um[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> [0m
[31mTablets<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule Rrule"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule [0m
[31mRrule"[0m[31m><content style WARFARIN: spl_medguide_table: [0m[31mCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium tablets?<[0m[31m/[0m[31mcontent[0m[31m><paragraph>Warfarin sodium tablets can [0m
[31mcause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. [0m
[31mWARFARIN: spl_medguide_table: <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>You may have a higher risk of bleeding if you take warfarin sodium tablets and: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>are [0m[1;31m65[0m[31m years of age or older <[0m[31m/[0m[31mitem[0m[31m><item>have a history of stomach or intestinal bleeding <[0m[31m/[0m[31mitem[0m[31m><item>have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have a history of [0m
[31mstroke, or &#x201C;mini-stroke&#x201D; [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have serious heart disease <[0m[31m/[0m[31mitem[0m[31m><item>have a low blood count or cancer <[0m[31m/[0m[31mitem[0m[31m><item>have had trauma, such as an[0m
[31maccident or surgery <[0m[31m/[0m[31mitem[0m[31m><item>have kidney problems <[0m[31m/[0m[31mitem[0m[31m><item>take other medicines that increase your risk of bleeding, including: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Square"[0m[31m><item>a medicine [0m
[31mthat contains heparin <[0m[31m/[0m[31mitem[0m[31m WARFARIN: spl_medguide_table: ><item>other medicines to prevent or treat blood clots <[0m[31m/[0m[31mitem[0m[31m><item>non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>take warfarin sodium for a long time. Warfarin sodium is the active ingredient in warfarin sodium tablets. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any[0m
[31mof your medicines or start any new medicines before you talk to your healthcare provider. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not take other medicines that contain warfarin sodium [0m
[31mwhile taking warfarin sodium tablets. WARFARIN: spl_medguide_table: content><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Get your regular blood test to check[0m
[31mfor your response to warfarin sodium tablets. <[0m[31m/[0m[31mcontent[0m[31m>This blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR [0m
[31mnumbers are best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: use_in_specific_populations: [0m[1;31m2[0m[31m Lactation Risk Summary Warfarin was not present in human milk from mothers treated with warfarin from a limited published study. Because of the [0m
[31mpotential for serious adverse reactions, including bleeding in a breastfed infant, consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for warfarin [0m
[31msodium and any potential adverse effects on the breastfed infant from warfarin sodium or from the underlying maternal condition before prescribing warfarin sodium to a lactating woman. Clinical [0m
[31mConsiderations Monitor breastfeeding infants for bruising or bleeding. Data Human Data Based on published data in [0m[1;31m15[0m[31m nursing mothers, warfarin was not detected in human milk. Among the [0m[1;31m15[0m[31m full-term [0m
[31mnewborns, [0m[1;31m6[0m[31m nursing infants had documented prothrombin times within the expected range. Prothrombin times were not obtained for the other [0m[1;31m9[0m[31m nursing infants. Effects in premature infants have not been [0m
[31mevaluated. [0m[1;31m8[0m[31m. WARFARIN: use_in_specific_populations: [0m[1;31m3[0m[31m Females and Males of Reproductive Potential Pregnancy Testing Warfarin sodium can cause fetal harm [0m[31m . Verify the pregnancy status of females of [0m
[31mreproductive potential prior to initiating warfarin sodium therapy. Contraception Females Advise females of reproductive potential to use effective contraception during treatment and for at least [0m[1;31m1[0m[31m [0m
[31mmonth after the final dose of warfarin sodium. [0m[1;31m8.4[0m[31m Pediatric Use Adequate and well-controlled studies with warfarin sodium have not been conducted in any pediatric population, and the optimum dosing, [0m
[31msafety, and efficacy in pediatric patients is unknown. Pediatric use of warfarin sodium is based on adult data and recommendations, and available limited pediatric data from observational studies and [0m
[31mpatient registries. Pediatric patients administered warfarin sodium should avoid any activity or sport that may result in traumatic injury. WARFARIN: use_in_specific_populations: The developing [0m
[31mhemostatic system in infants and children results in a changing physiology of thrombosis and response to anticoagulants. Dosing of warfarin in the pediatric population varies by patient age, with [0m
[31minfants generally having the highest, and adolescents having the lowest milligram per kilogram dose requirements to maintain target INRs. Because of changing warfarin requirements due to age, [0m
[31mconcomitant medications, diet, and existing medical condition, target INR ranges may be difficult to achieve and maintain in pediatric patients, and more frequent INR determinations are recommended. [0m
[31mBleeding rates varied by patient population and clinical care center in pediatric observational studies and patient registries. Infants and children receiving vitamin K-supplemented nutrition, [0m
[31mincluding infant formulas, may be resistant to warfarin therapy, while human milk-fed infants may be sensitive to warfarin therapy. [0m[1;31m8[0m[31m. WARFARIN: use_in_specific_populations: [0m[1;31m5[0m[31m Geriatric Use Of the [0m
[31mtotal number of patients receiving warfarin sodium in controlled clinical trials for which data were available for analysis, [0m[1;31m1885[0m[31m patients [0m[1;31m([0m[1;31m24.4[0m[31m%[0m[1;31m)[0m[31m were [0m[1;31m65[0m[31m years and older, while [0m[1;31m185[0m[31m patients [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mwere [0m[1;31m75[0m[31m years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled [0m
[31mout. Patients [0m[1;31m60[0m[31m years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin [0m[31m . Warfarin sodium is contraindicated in any unsupervised patient with [0m
[31msenility. Conduct more frequent monitoring for bleeding with administration of warfarin sodium to elderly patients in any situation or with any physical condition where added risk of hemorrhage is [0m
[31mpresent. WARFARIN: use_in_specific_populations: Consider lower initiation and maintenance doses of warfarin sodium in elderly patients [0m[31m . [0m[1;31m8.6[0m[31m Renal Impairment Renal clearance is considered to be a [0m
[31mminor determinant of anticoagulant response to warfarin. No dosage adjustment is necessary for patients with renal impairment. Instruct patients with renal impairment taking warfarin to monitor their [0m
[31mINR more frequently [0m[31m . [0m[1;31m8.7[0m[31m Hepatic Impairment Hepatic impairment can potentiate the response to warfarin through impaired synthesis of clotting factors and decreased metabolism of warfarin. Conduct [0m
[31mmore frequent monitoring for bleeding when using warfarin sodium in these patients.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products, and inhibitors and inducers of [0m
[31mCYP2C9, 1A2, or 3A4. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium or increased risks for bleeding. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m General [0m
[31mInformation Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism [0m[1;31m([0m[31mimpaired[0m
[31mhemostasis, reduced clotting factor synthesis[0m[1;31m)[0m[31m, competitive antagonism [0m[1;31m([0m[31mvitamin K[0m[1;31m)[0m[31m, and alteration of the physiologic control loop for vitamin K metabolism [0m[1;31m([0m[31mhereditary resistance[0m[1;31m)[0m[31m. Pharmacokinetic [0m
[31mmechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. WARFARIN: drug_interactions: It is important to note that some[0m
[31mdrugs may interact by more than one mechanism. More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, [0m
[31mincluding drugs intended for short-term use [0m[1;31m([0m[31me.g., antibiotics, antifungals, corticosteroids[0m[1;31m)[0m[31m [0m[1;31m[[0m[31m see Boxed Warning [0m[1;31m][0m[31m. Consult the labeling of all concurrently used drugs to obtain further information [0m
[31mabout interactions with warfarin sodium or adverse reactions pertaining to bleeding. [0m[1;31m7.2[0m[31m CYP450 Interactions CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, [0m
[31m1A2, and 3A4. The more potent warfarin S -enantiomer is metabolized by CYP2C9 while the R -enantiomer is metabolized by CYP1A2 and 3A4. WARFARIN: drug_interactions: Inhibitors of CYP2C9, 1A2, and/or [0m
[31m3A4 have the potential to increase the effect [0m[1;31m([0m[31mincrease INR[0m[1;31m)[0m[31m of warfarin by increasing the exposure of warfarin. Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect [0m[1;31m([0m[31mdecrease[0m
[31mINR[0m[1;31m)[0m[31m of warfarin by decreasing the exposure of warfarin. Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table [0m[1;31m2[0m[31m ; however, this list should not be considered all-inclusive. [0m
[31mConsult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, [0m
[31mstopping, or changing dose of concomitant medications. WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of [0m
[31mCYP450 Interactions with Warfarin Enzyme Inhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, [0m
[31msulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, [0m
[31menoxacin, famotidine, fluvoxamine WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, [0m
[31mticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, [0m
[31matazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, [0m
[31mfosamprenav WARFARIN: drug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, [0m
[31mranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, [0m
[31mnafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN:[0m
[31mdrug_interactions: Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: [0m
[31mdrug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents[0m
[31maspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, [0m
[31mketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, [0m
[31mparoxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or [0m
[31mantifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic [0m
[31mor antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, [0m
[31mwell-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with [0m
[31mbotanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals [0m
[31mmay cause bleeding events when taken alone [0m[1;31m([0m[31me.g.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31mMedication Guide[0m[1;31m)[0m[31m. Instructions for Patients Advise [0m
[31mpatients to: Strictly adhere to the prescribed dosage schedule [0m[31m . If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose [0m
[31mof warfarin sodium the next day to make up for missed doses [0m[31m . Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy [0m[31m . Be aware that if therapy with [0m
[31mwarfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m days [0m[31m . WARFARIN: information_for_patients: Avoid any activity or sport that may result in [0m
[31mtraumatic injury [0m[31m . And to tell their physician if they fall often as this may increase their risk for complications. Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid [0m
[31mdrastic changes in dietary habits, such as eating large amounts of leafy, green vegetables [0m[31m . Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever [0m[31m . [0m
[31mImmediately contact their physician when experiencing pain and discoloration of the skin [0m[1;31m([0m[31ma purple bruise like rash[0m[1;31m)[0m[31m mostly on areas of the body with a high fat content, such as breasts, thighs, [0m
[31mbuttocks, hips and abdomen [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. WARFARIN: information_for_patients: Immediately contact their physician when experiencing any unusual symptom or pain since [0m
[31mwarfarin sodium may cause small cholesterol or athero emboli. On feet it may appear as a sudden cool, painful, purple discoloration of [0m[1;31mtoe[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m or forefoot [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. [0m
[31mImmediately contact their physician when taking warfarin sodium after any heparin formulation therapy and experiencing bloody or black stools or appearence of bruises, or bleeding [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. To tell all of their healthcare professionals and dentists that they are taking warfarin sodium. This should be done before they have any surgery or dental procedure [0m[1;31m[[0m[31m see [0m
[31mDosage and Administration [0m[1;31m([0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Carry identification stating that they are taking warfarin sodium. Bleeding Risks Advise patients to: Notify their physician immediately if any unusual bleeding or[0m
[31msymptoms occur. WARFARIN: information_for_patients: Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, [0m
[31mnosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness [0m[31m . Concomitant Medications and Botanicals [0m
[1;31m([0m[31mHerbals[0m[1;31m)[0m[31m Advise patients to: Not take or discontinue any other drug, including salicylates [0m[1;31m([0m[31me.g., aspirin and topical analgesics[0m[1;31m)[0m[31m, other over-the-counter drugs, and botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products except[0m
[31mon advice of your physician [0m[31m . Pregnancy and Nursing Advise patients to: Notify their physician if they are pregnant or planning to become pregnant or considering breast feeding [0m[1;31m[[0m[31m see Use in Specific [0m
[31mPopulations [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m , [0m[1;31m8.2[0m[31m , [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of [0m
[31mthromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [0m[31m . Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a [0m
[31mpattern of congenital malformations in about [0m[1;31m5[0m[31m% of exposed offspring. Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an [0m
[31madequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks [0m
[31mof warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman. WARFARIN: pregnancy: Adverse outcomes in pregnancy occur regardless of the health of the mother[0m
[31mor the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk [0m
[31mof major birth defects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions In humans, warfarin [0m
[31mcrosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in [0m
[31mabout [0m[1;31m5[0m[31m% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses [0m[1;31m([0m[31mchondrodysplasia punctata[0m[1;31m)[0m[31m and growth retardation [0m[1;31m([0m[31mincluding low birth [0m
[31mweight[0m[1;31m)[0m[31m. WARFARIN: pregnancy: Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker [0m
[31mmalformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse [0m
[31mpregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. [0m
[31mDiscontinue warfarin sodium and consider alternative anticoagulants if necessary. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Calciphylaxis: Fatal and serious cases have occurred. Discontinue warfarin sodium and consider alternative [0m
[31manticoagulation therapy. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Systemic atheroemboli and cholesterol microemboli: Some cases have [0m
[31mprogressed to necrosis or death. Discontinue warfarin sodium if such emboli occur. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m: Initial therapy with warfarin sodium in HIT has resulted in cases of [0m
[31mamputation and death. WARFARIN: warnings_and_cautions: Warfarin sodium may be considered after platelet count has normalized. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m Pregnant women with mechanical heart valves: Warfarin sodium may [0m
[31mcause fetal harm; however, the benefits may outweigh the risks. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Hemorrhage Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk [0m
[31mfactors for bleeding include high intensity of anticoagulation [0m[1;31m([0m[31mINR [0m[1;31m>[0m[31m [0m[1;31m4[0m[1;31m)[0m[31m, age greater than or equal to [0m[1;31m65[0m[31m, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, [0m
[31mcerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [0m[31m , certain concomitant drugs [0m[31m , and long duration of warfarin therapy. Perform regular monitoring of INR [0m
[31min all treated patients. WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration [0m
[31mof therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR [0m
[31mlevels achieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct [0m
[31mpatients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other[0m
[31mtissues, which is an uncommon but serious risk [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin[0m
[31msodium therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to [0m
[31mdetermine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin [0m
[31msodium therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium [0m
[31muremic arteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat [0m
[31mcalciphylaxis as appropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: [0m[1;31m14[0m[31m CLINICAL STUDIES [0m[1;31m14.1[0m[31m Atrial Fibrillation In five prospective, randomized, controlled clinical trials involving [0m[1;31m3711[0m[31m patients with non-rheumatic AF, warfarin [0m
[31msignificantly reduced the risk of systemic thromboembolism including stroke [0m[1;31m([0m[31msee Table [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m. The risk reduction ranged from [0m[1;31m60[0m[31m% to [0m[1;31m86[0m[31m% in all except one trial [0m[1;31m([0m[31mCAFA: [0m[1;31m45[0m[31m%[0m[1;31m)[0m[31m, which was stopped early due [0m
[31mto published positive results from two of these trials. The incidence of major bleeding in these trials ranged from [0m[1;31m0.6[0m[31m% to [0m[1;31m2.7[0m[31m% [0m[1;31m([0m[31msee Table [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m. Table [0m[1;31m4[0m[31m: Clinical Studies of Warfarin in Non-Rheumatic [0m
[31mAF Patients * N Thromboembolism % Major Bleeding Study Warfarin-Treated Patients Control Patients PT Ratio INR % Risk Reduction p -value Warfarin-Treated Patients Control Patients AFASAK [0m[1;31m335[0m[31m [0m[1;31m336[0m[31m [0m[1;31m1.5[0m[31m [0m
[31mto [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m. WARFARIN: clinical_studies: [0m[1;31m8[0m[31m to [0m[1;31m4.2[0m[31m [0m[1;31m60[0m[31m [0m[1;31m0.027[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m SPAF [0m[1;31m210[0m[31m [0m[1;31m211[0m[31m [0m[1;31m1.3[0m[31m to [0m[1;31m1.8[0m[31m [0m[1;31m2[0m[31m to [0m[1;31m4.5[0m[31m [0m[1;31m67[0m[31m [0m[1;31m0.01[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m1.9[0m[31m BAATAF [0m[1;31m212[0m[31m [0m[1;31m208[0m[31m [0m[1;31m1.2[0m[31m to [0m[1;31m1.5[0m[31m [0m[1;31m1.5[0m[31m to [0m[1;31m2.7[0m[31m [0m[1;31m86[0m[31m < [0m[1;31m0.05[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m0.5[0m[31m CAFA [0m[1;31m187[0m[31m [0m[1;31m191[0m[31m [0m[1;31m1.3[0m[31m to [0m[1;31m1.6[0m[31m [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m [0m[1;31m45[0m[31m [0m
[1;31m0.25[0m[31m [0m[1;31m2.7[0m[31m [0m[1;31m0.5[0m[31m SPINAF [0m[1;31m260[0m[31m [0m[1;31m265[0m[31m [0m[1;31m1.2[0m[31m to [0m[1;31m1.5[0m[31m [0m[1;31m1.4[0m[31m to [0m[1;31m2.8[0m[31m [0m[1;31m79[0m[31m [0m[1;31m0.001[0m[31m [0m[1;31m2.3[0m[31m [0m[1;31m1.5[0m[31m * All study results of warfarin vs. WARFARIN: clinical_studies: control are based on intention-to-treat analysis and include ischemic[0m
[31mstroke and systemic thromboembolism, excluding hemorrhagic stroke and transient ischemic attacks. Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with [0m
[31mwarfarin sodium [0m[31m . [0m[1;31m14.2[0m[31m Mechanical and Bioprosthetic Heart Valves In a prospective, randomized, open-label, positive-controlled study in [0m[1;31m254[0m[31m patients with mechanical prosthetic heart valves, the [0m
[31mthromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients [0m[1;31m([0m[31mp < [0m[1;31m0.005[0m[1;31m)[0m[31m and [0m
[31mpentoxifylline/aspirin-treated patients [0m[1;31m([0m[31mp < [0m[1;31m0.05[0m[1;31m)[0m[31m. The results of this study are presented in Table [0m[1;31m5[0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: dosage_and_administration: [0m[1;31m2[0m[31m Recommended Target INR Ranges and Durations for Individual Indications An INR of greater than [0m[1;31m4[0m[31m appears to provide no additional therapeutic benefit in [0m
[31mmost patients and is associated with a higher risk of bleeding. Venous Thromboembolism [0m[1;31m([0m[31mincluding deep venous thrombosis [0m[1;31m[[0m[31mDVT[0m[1;31m][0m[31m and PE[0m[1;31m)[0m[31m Adjust the warfarin dose to maintain a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mINR [0m
[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m for all treatment durations. The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient [0m[1;31m([0m[31mreversible[0m[1;31m)[0m[31m risk factor, treatment [0m
[31mwith warfarin for [0m[1;31m3[0m[31m months is recommended. For patients with an unprovoked DVT or PE, treatment with warfarin is recommended for at least [0m[1;31m3[0m[31m months. After [0m[1;31m3[0m[31m months of therapy, evaluate the risk-benefit[0m
[31mratio of long-term treatment for the individual patient. WARFARIN: dosage_and_administration: For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended. [0m
[31mFor a patient receiving long-term anticoagulant treatment, periodically reassess the risk-benefit ratio of continuing such treatment in the individual patient. Atrial Fibrillation In patients with [0m
[31mnon-valvular AF, anticoagulate with warfarin to target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m. In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke [0m[1;31m([0m[31mi.e., having any of the[0m
[31mfollowing features: prior ischemic stroke, transient ischemic attack, or systemic embolism, or [0m[1;31m2[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or severely impaired left [0m
[31mventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. WARFARIN: dosage_and_administration: In [0m
[31mpatients with non-valvular AF that is persistent or paroxysmal and at an intermediate risk of ischemic stroke [0m[1;31m([0m[31mi.e., having [0m[1;31m1[0m[31m of the following risk factors: age greater than [0m[1;31m75[0m[31m years, moderately or [0m
[31mseverely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus[0m[1;31m)[0m[31m, long-term anticoagulation with warfarin is recommended. For patients with AF [0m
[31mand mitral stenosis, long-term anticoagulation with warfarin is recommended. For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR [0m
[31mmay be increased and aspirin added depending on valve type and position, and on patient factors. WARFARIN: dosage_and_administration: Mechanical and Bioprosthetic Heart Valves For patients with a [0m
[31mbileaflet mechanical valve or a Medtronic Hall [0m[1;31m([0m[31mMinneapolis, MN[0m[1;31m)[0m[31m tilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement, therapy with warfarin to a [0m
[31mtarget INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m is recommended. For patients with tilting disk valves and bileaflet mechanical valves in the mitral position, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m [0m
[31mto [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with caged ball or caged disk valves, therapy with warfarin to a target INR of [0m[1;31m3[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2.5[0m[31m to [0m[1;31m3.5[0m[1;31m)[0m[31m is recommended. For patients with a bioprosthetic valve in the[0m
[31mmitral position, therapy with warfarin to a target INR of [0m[1;31m2[0m[31m. WARFARIN: dosage_and_administration: [0m[1;31m5[0m[31m [0m[1;31m([0m[31mrange, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m for the first [0m[1;31m3[0m[31m months after valve insertion is recommended. If additional risk [0m
[31mfactors for thromboembolism are present [0m[1;31m([0m[31mAF, previous thromboembolism, left ventricular dysfunction[0m[1;31m)[0m[31m, a target INR of [0m[1;31m2.5[0m[31m [0m[1;31m([0m[31mrange [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m is recommended. Post-Myocardial Infarction For high-risk [0m
[31mpatients with MI [0m[1;31m([0m[31me.g., those with a large anterior MI, those with significant heart failure, those with intracardiac thrombus visible on transthoracic echocardiography, those with AF, and those with [0m
[31ma history of a thromboembolic event[0m[1;31m)[0m[31m, therapy with combined moderate-intensity [0m[1;31m([0m[31mINR, [0m[1;31m2[0m[31m to [0m[1;31m3[0m[1;31m)[0m[31m warfarin plus low-dose aspirin [0m[1;31m([0m[31mâ‰¤ [0m[1;31m100[0m[31m mg/day[0m[1;31m)[0m[31m for at least [0m[1;31m3[0m[31m months after the MI is recommended.         [0m
[31mSOURCE:WARFARIN label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI have attempted to find information on whether WARFARIN increases or [0m
[32mdecreases the risk of aplastic anemia by querying FDAHandler. However, FDAHandler has responded with DO-NOT-KNOW to both inquiries, indicating that the FDA label for WARFARIN does not specify any [0m
[32minformation regarding its effects on the risk of aplastic anemia. This suggests that there may not be a known effect, or that any potential effect has not been sufficiently studied or documented to be[0m
[32mincluded in the label.[0m

[32mGiven the lack of information from the FDA label, I cannot provide a definitive answer to the question of whether WARFARIN increases or decreases the risk of aplastic anemia.[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether WARFARIN increases the risk of aplastic anemia and received a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"I then asked FDAHandler whether WARFARIN decreases the risk of aplastic anemia and again received a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"These responses indicate that the FDA label for WARFARIN does not specify any information regarding its effects on the risk of aplastic anemia."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether WARFARIN increases the risk of aplastic anemia and received a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"I then asked FDAHandler whether WARFARIN decreases the risk of aplastic anemia and again received a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"These responses indicate that the FDA label for WARFARIN does not specify any information regarding its effects on the risk of aplastic anemia."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether WARFARIN increases the risk of aplastic anemia and received a DO-NOT-KNOW response.[0m
[1;31m2[0m[31m. I then asked FDAHandler whether WARFARIN decreases the risk of aplastic anemia and again received a DO-NOT-KNOW response.[0m
[1;31m3[0m[31m. These responses indicate that the FDA label for WARFARIN does not specify any information regarding its effects on the risk of aplastic anemia.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent and logical. The user has checked with FDAHandler for information on WARFARIN's effect on the risk of aplastic anemia and received DO-NOT-KNOW [0m
[32mresponses for both increasing and decreasing the risk. This indicates that there is no information available on the FDA label regarding this specific effect. The user has clearly expressed why it was [0m
[32mnot possible to answer the question, which is in line with the instructions provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent and logical. The user has checked with FDAHandler for information on WARFARIN's effect on the risk of aplastic anemia and received DO-NOT-KNOW [0m
[34mresponses for both increasing and decreasing the risk. This indicates that there is no information available on the FDA label regarding this specific effect. The user has clearly expressed why it was [0m
[34mnot possible to answer the question, which is in line with the instructions provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent and logical. The user has checked with FDAHandler for information on WARFARIN's effect on the risk of aplastic anemia and received DO-NOT-KNOW [0m
[31mresponses for both increasing and decreasing the risk. This indicates that there is no information available on the FDA label regarding this specific effect. The user has clearly expressed why it was [0m
[31mnot possible to answer the question, which is in line with the instructions provided.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for WARFARIN does not specify any information regarding its effects on the risk of aplastic anemia. This was determined by querying FDAHandler about whether WARFARIN increases or [0m
[32mdecreases the risk of aplastic anemia, to which the response was DO-NOT-KNOW in both cases. Therefore, based on the available FDA label data, it is not possible to determine if WARFARIN has any effect[0m
[32mon the risk of developing aplastic anemia.[0m
